Biotoxtech Co (086040) Fair Value & Analysis
Healthcare · KR · Market cap 32.1B KRW
Fair value as of: Jul 20, 2026
From 18 valuation models · updated 20 days ago
Share price +1.3% over the past month.
A solid business, but screening 34% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,745 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 1,983 KRW – 12,100 KRW · fair‑value band 1,037 KRW – 1,745 KRW · the 2,255 KRW price screens above the 1,481 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Biotoxtech Co (086040) currently trades at 2,255 KRW, while our model-based Fair Value estimate is 1,481 KRW, implying the stock looks roughly 34.3% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Biotoxtech Co generated revenue of 37.6B KRW at a net margin of 18.3%. Revenue grew 9.1% year over year. Net debt stands at 43.7B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 1,037 KRW (bear case) to 1,745 KRW (bull case); at 2,255 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -13% fair-value upside, at -34%, 086040 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 18 models by family
Widest divergence: Growth DCF (5,622 KRW) versus Earnings-Based (868.27 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea.
Full company description
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and business consulting and vicegerent of nonclinical trial activities. The company's safety evaluation research field includes general toxicity studies, carcinogenicity studies, local toxicity studies, reproductive and developmental studies, genotoxicity studies, immunotoxicity studies, safety pharmacology, ecotoxicology studies, histopathology/clinical pathology, and juvenile animal toxicity studies. Biotoxtech Co., Ltd. was founded in 2000 and is headquartered in Cheongwon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Biotoxtech Co reported revenue of 47.0B KRW in FY2025 versus 32.7B KRW in FY2021, a compound +9.5%/yr. Reported net income was 1.2B KRW in FY2025, compounding −36.4%/yr from FY2021.
086040 screens 34% overvalued. Compare with MEDIPOST Co →
Peer Group
Health Care · 2228 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| MEDIPOST Co 078160 | 8,150 KRW | 4,269 KRW | -48% |
| Bioneer Corporation 064550 | 6,020 KRW | 8,312 KRW | +38% |
| Macrogen, Inc 038290 | 11,090 KRW | 4,457 KRW | -60% |
| Cell Biotech Co 049960 | 14,980 KRW | 19,433 KRW | +30% |
| Panagene Inc 046210 | 1,068 KRW | 480.36 KRW | -55% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
| GSK plc GSKN | 917.00 MXN | 1,078 MXN | +18% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
Compare Biotoxtech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Biotoxtech Co (086040) overvalued or undervalued?
What is the fair value of 086040?
What is the quality score of 086040?
What is the revenue of Biotoxtech Co (086040)?
What is the net profit margin of 086040?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Biotoxtech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.